<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(9)</volume><submitter>Rao R</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Trousseau syndrome (TS) refers to spontaneous, recurrent, and wandering arterial and venous thromboembolic events in patients with tumors. It results from abnormalities in coagulation and fibrinolytic mechanisms of varying degrees throughout the course of the disease. It has a high fatality rate, and it is commonly seen in patients with highly invasive tumors, such as lung, pancreatic, gastrointestinal, and breast cancers; however, to date, there has been no report of TS combined with chordoma.&lt;h4>Case description&lt;/h4>A 56-year-old male with a diagnosis of chordoma underwent surgery, immunotherapy, immunotherapy combined with antiangiogenic therapy, chemotherapy combined with immunotherapy, and proton therapy for localized metastases. Subsequent to the worsening of chest</pubmed_abstract><journal>Journal of thoracic disease</journal><pagination>6249-6262</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11494589</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Chordoma combined with Trousseau syndrome: a case report and literature review.</pubmed_title><pmcid>PMC11494589</pmcid><pubmed_authors>Lin P</pubmed_authors><pubmed_authors>Rao R</pubmed_authors><pubmed_authors>Mutoh T</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Ito S</pubmed_authors><pubmed_authors>Yu Z</pubmed_authors><pubmed_authors>Xu J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Chordoma combined with Trousseau syndrome: a case report and literature review.</name><description>&lt;h4>Background&lt;/h4>Trousseau syndrome (TS) refers to spontaneous, recurrent, and wandering arterial and venous thromboembolic events in patients with tumors. It results from abnormalities in coagulation and fibrinolytic mechanisms of varying degrees throughout the course of the disease. It has a high fatality rate, and it is commonly seen in patients with highly invasive tumors, such as lung, pancreatic, gastrointestinal, and breast cancers; however, to date, there has been no report of TS combined with chordoma.&lt;h4>Case description&lt;/h4>A 56-year-old male with a diagnosis of chordoma underwent surgery, immunotherapy, immunotherapy combined with antiangiogenic therapy, chemotherapy combined with immunotherapy, and proton therapy for localized metastases. Subsequent to the worsening of chest</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2025-04-04T03:05:28.558Z</modification><creation>2025-04-04T03:05:28.558Z</creation></dates><accession>S-EPMC11494589</accession><cross_references><pubmed>39444889</pubmed><doi>10.21037/jtd-24-1232</doi></cross_references></HashMap>